Skip to main content

Table 3 Total population size of the benefit cohorts and numbers of cases of chronic disease averted

From: A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000–2020)

  Benefit cohort 1: Protected from acquiring infection and, therefore, subsequently protected from any clinical disease (millions) Benefit cohort 2: Subclinical morbidity prevented from progressing (millions) Benefit cohort 3: Clinical disease improved (millions) Total (millions)
Population size
 Hydrocele 16.23 9.26 9.37 34.86
 Lymphedema 9.74 5.56 8.30 23.60
 Total 25.97 14.82 17.67 58.46
Cases of chronic disease averted
 Hydrocele 16.23 9.26 1.82 27.31
 Lymphedema 9.74 5.56 1.64 16.93
 Total 25.97 14.82 3.46 44.25
  1. Note that the benefit cohorts quantify the individuals who are projected to benefit directly in terms of prevented or alleviated clinical disease by the treatments given between 2000–2020, i.e. they capture the long-term health benefits of these treatments beyond the year 2020